IP Library Granted Patent US 11,041,172
Granted Patent B2
US 11,041,172 · App. 16/911,156 · Granted Jun 22, 2021

Homology dependent repair genome editing

Inventor: Tomá{hacek over (s)} {hacek over (C)}ermák (Brookline, MA)
Assignee: Inari Agriculture, Inc.
C12N15/902C12N9/22C12N15/907C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,041,172
App. No.
16/911,156
Granted
Jun 22, 2021
Kind
B2
Abstract

Eukaryotic cells and related reagents, systems, methods, and compositions for increasing the frequency of homology directed repair (HDR) of target editing sites with genome editing molecules are provided.

Claims (35)

1. A method for increasing Homology Directed Repair (HDR)-mediated genome modification of a target editing site of a eukaryotic cell genome, comprising:

providing genome-editing molecules and heterologous HDR promoting agents to a eukaryotic cell, wherein the genome editing molecules comprise: (i) at least one sequence-specific endonuclease which cleaves a DNA sequence in the target editing site or at least one polynucleotide encoding the sequence-specific endonuclease; and (ii) a donor template DNA molecule having homology to the target editing site; and wherein the HDR promoting agents comprise a single-stranded DNA annealing protein (SSAP), an exonuclease which can convert a double stranded DNA substrate to a single stranded DNA product, and a single stranded DNA binding protein (SSB);

whereby the genome editing molecules and HDR promoting agents provide for modification of the target editing site of the eukaryotic cell genome with the donor template DNA by HDR at a frequency that is increased in comparison to a control.

2. The method of claim 1 , wherein the sequence-specific endonuclease comprises an RNA-guided nuclease or a polynucleotide encoding an RNA-guided nuclease and a guide RNA or a polynucleotide encoding a guide RNA.

3. The method of claim 2 , wherein the RNA-guided nuclease is selected from the group consisting of a type II Cas nuclease, a Cas9 nuclease, a type V Cas nuclease, a Cas12a nuclease, a Cas12b nuclease, a Cas12c nuclease, a CasY nuclease, a CasX nuclease, Cas12i, Cas14 and an engineered nuclease.

4. The method of claim 1 , wherein the donor DNA molecule is provided on a circular DNA vector, geminivirus replicon, or as a linear DNA fragment.

5. The method of claim 1 , wherein the donor DNA molecule is flanked by an endonuclease recognition sequence.

6. The method of claim 1 , wherein the SSAP is selected from the group consisting of RecT/Redβ-, ERF-, and a RAD52-family protein.

7. The method of claim 6 , wherein the RecT/Redβ-family protein is selected from the group consisting of a Rac bacterial prophage RecT protein, a bacteriophage λ beta protein, a bacteriophage SPP1 35 protein, and a protein having at least 70% sequence identity to SEQ ID NO: 1, 2, or 3.

8. The method of claim 1 , wherein the exonuclease has 5′ to 3′ exonuclease activity and can recognize a blunt ended dsDNA substrate, a dsDNA substrate having an internal break in one strand, a dsDNA substrate having a 5′ overhang, or a dsDNA substrate having a 3′ overhang.

9. The method of claim 1 , wherein the exonuclease is selected from the group consisting of a bacteriophage lambda exo protein, an Rac prophage RecE exonuclease, an Artemis protein, an Apollo protein, a DNA2 exonuclease, an Exo1 exonuclease, a herpesvirus SOX protein, UL12 exonuclease, an enterobacterial exonuclease VIII, a T7 phage exonuclease, Exonuclease III, a Trex2 exonuclease, and a protein having at least 70% sequence identity to SEQ ID NO: 8, 9, 136, 137, 138, 139, 140, 141, 142, 143, 144, or 145.

10. The method of claim 1 , wherein the SSB has at least 70% sequence identity to SEQ ID NO:31, 34-131, or 132.

11. The method of claim 1 , wherein the frequency of HDR is increased by at least 2-fold in comparison to a control method wherein a control eukaryotic cell is provided with the genome editing molecules but is not exposed to at least one of said HDR promoting agents.

12. The method of claim 1 , wherein the frequency of non-homologous end-joining (NHEJ) is maintained or decreased by at least 2-fold in comparison to a control method wherein a control eukaryotic cell is provided with the genome editing molecules but is not exposed to at least one of said HDR promoting agents.

13. The method of claim 1 , where the eukaryotic cell is a plant cell.

14. A system for increasing Homology Directed Repair (HDR)-mediated genome modification of a target editing site of an animal cell, comprising:

(a) an animal cell;

(b) heterologous HDR promoting agents comprising a single-stranded DNA annealing protein (SSAP), an exonuclease which can convert a double stranded DNA substrate to a single stranded DNA product, and a single stranded DNA binding protein (SSB); and

(c) genome editing molecule(s) comprising at least one sequence-specific endonuclease which cleaves a DNA sequence in the target editing site or at least one polynucleotide encoding the sequence-specific endonuclease and a donor template DNA molecule having homology to the target editing site;

wherein the animal cell is associated with, contacts, or contains an effective amount of the HDR promoting agents and the genome editing molecule(s).

15. The system of claim 14 , wherein the genome editing molecules or sequence-specific endonuclease is selected from the group consisting of an RNA-guided nuclease or a polynucleotide encoding an RNA-guided nuclease and a guide RNA or a polynucleotide encoding a guide RNA.

16. The system of claim 15 , wherein the RNA-guided nuclease is selected form the group consisting of a type II Cas nuclease, a Cas9 nuclease, a type V Cas nuclease, a Cas12a nuclease, a Cas12b nuclease, a Cas12c nuclease, a CasY nuclease, a CasX nuclease, Cas12i, Cas14 and an engineered nuclease.

17. The system of claim 14 , wherein the SSAP is selected form the group consisting of a RecT/Redβ-, ERF-, and a RAD52-family protein.

18. The system of claim 17 , wherein the RecT/Redβ-family protein is selected from the group consisting of a Rac bacterial prophage RecT protein, a bacteriophage λ beta protein, and a bacteriophage SPP1 35 protein.

19. The system of claim 17 , wherein the exonuclease has 5′ to 3′ exonuclease activity and can recognize a blunt ended dsDNA substrate, a dsDNA substrate having an internal break in one strand, a dsDNA substrate having a 5′ overhang, or a dsDNA substrate having a 3′ overhang.

20. The system of claim 14 , wherein the exonuclease is selected from the group consisting of bacteriophage lambda exo protein, an Rac prophage RecE exonuclease, an Artemis protein, an Apollo protein, a DNA2 exonuclease, an Exo1 exonuclease, a herpesvirus SOX protein, UL12 exonuclease, an enterobacterial exonuclease VIII, a T7 phage exonuclease, E. coli Exonuclease III, a mammalian Trex2 exonuclease, and a protein having at least 70% sequence identity to SEQ ID NO: 8, 9, 136, 137, 138, 139, 140, 141, 142, 143, 144, or 145.

21. The system of claim 14 , wherein the frequency of HDR is increased by at least 2-fold in comparison to a control system wherein a control animal cell is provided with the genome editing molecules but is not exposed to at least one of said HDR promoting agents.

22. The system of claim 14 , wherein the SSAP, the exonuclease, and/or the single stranded DNA binding protein further comprise an operably linked nuclear localization signal (NLS) or a cell-penetrating peptide (CPP).

23. The system of claim 14 , wherein the animal cell is a mammalian cell.

24. A method of genetic engineering of a eukaryotic cell comprising providing to the eukaryotic cell: i) at least one sequence-specific endonuclease, ii) a donor template DNA molecule having homology to a target editing site in the eukaryotic cell, iii) a heterologous single-stranded DNA annealing protein (SSAP), iv) a heterologous exonuclease which can convert a double stranded DNA substrate to a single stranded DNA product, and v) a heterologous single stranded DNA binding protein (SSB), wherein the target editing site of the cell is modified by the donor template DNA molecule.

25. The method of claim 24 , wherein the at least one sequence-specific endonuclease comprises an RNA-guided nuclease or a polynucleotide encoding an RNA-guided nuclease and a guide RNA or a polynucleotide encoding a guide RNA.

26. The method of claim 24 , further comprising detecting the modification.

27. The method of claim 24 , wherein the target editing site is in a protein coding sequence or a promoter.

28. The method of claim 24 , wherein the modification of the target editing site is an insertion, a deletion, or a substitution.

29. A kit comprising nucleic acids encoding i) at least one sequence-specific endonuclease, ii) a donor template DNA molecule having homology to a target editing site in the eukaryotic cell, iii) a single-stranded DNA annealing protein (SSAP), iv) an exonuclease which can convert a double stranded DNA substrate to a single stranded DNA product, and v) a single stranded DNA binding protein (SSB) and instructions for use for genetically engineering a eukaryotic cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2021
From: INARI AGRICULTURE, INC.
To: INARI AGRICULTURE TECHNOLOGY, INC.
Reel/Frame 057507/0633 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME PREVIOUSLY RECORDED AT REEL: 055374 FRAME: 0845. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Mar 10, 2021
From: CERMÁK, TOMÁS
To: INARI AGRICULTURE, INC.
Reel/Frame 055557/0410 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2021
From: CERMÁK, TOMÁ?
To: INARI AGRICULTURE, INC.
Reel/Frame 055374/0845 →
Continuity (2)
Provisional Application 62866317 · Jun 25, 2019
Related Publication 20200407754A1 · Dec 31, 2020
Cited By (6)
US 12,195,772 US 12,270,036 US 12,305,175 US 12,344,849 US 12,529,062 US 12,723,266